Navigation Links
EpiCept Reports Second Quarter 2013 Operating and Financial Results
Date:7/31/2013

t levels through the close of the merger with Immune.

Other Income (Expense)Other income (expense) in the second quarter of 2013 amounted to net expense of $0.2 million compared with net expense of $0.9 million in the second quarter of 2012.  Other income (expense) in the six months ended June 30, 2013 amounted to net expense of $0.4 million compared with net expense of $1.9 million in the six months ended June 30, 2012.  The primary component of other expense in 2013 was interest expense related primarily to the Company's senior secured term loan.  The primary components of other expense in 2012 were warrant amendment expense of $0.9 million, interest expense of $0.7 million related primarily to the Company's senior secured term loan and a foreign exchange loss of $0.3 million.

About EpiCept CorporationEpiCept is focused on the development and commercialization of pharmaceutical products for the treatment of pain and cancer. The Company's pain portfolio includes AmiKet™, a prescription topical analgesic cream in late-stage clinical development designed to provide effective long-term relief of pain associated with peripheral neuropathies.  The Company's product Ceplene®, when used concomitantly with low-dose IL-2, is intended as remission maintenance therapy in the treatment of AML for adult patients who are in their first complete remission.  The Company sold all of its rights to Ceplene® in Europe and certain Pacific Rim countries and a portion of its remaining Ceplene® inventory to Meda AB in June 2012.  Ceplene® is licensed to MegaPharm Ltd. to market and sell in Israel and EpiCept has retained its rights to Ceplene® in all other countries, including countries in North and South America.  The Company has other oncology drug candidates in clinical development that were discovered using in-house technology and have been show
'/>"/>

SOURCE EpiCept Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
2. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
3. Interleukin Genetics Reports Third Quarter 2011 Financial Results
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Nile Therapeutics Reports 2011 Third Quarter Financial Results
6. Pharmasset Reports Fiscal Year End 2011 Financial Results
7. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
8. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
9. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
10. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
11. Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 Dr. Jason Wendel – recipient of ... one of the Top 10 Plastic Surgeon Specialists for Nashville, ... products. His complete line includes a Hydration Booster, Retexturing Night ... face and skin a younger, more radiant appearance while protecting ... is different, that is why at Dr. J. J. Wendel ...
(Date:7/28/2014)... 2014 Sapphire Energy, Inc. , a ... appointment of biotechnology veteran James Levine as ... Levine replaces Cynthia ,CJ, Warner, who is stepping down ... of the company,s board of directors. "The ... deliver commercial scale algae-based fuels has been tremendous, from ...
(Date:7/28/2014)... Research and Markets has announced ... 2014-2018" report to their offering. ... biology covers the designing and engineering of completely new ... redesigning of natural biological systems that provide improved and ... of extreme genetic engineering because it not only alters ...
(Date:7/28/2014)... , July 28, 2014   Propeller Health , ... announced the hire of Brad Towle as ... be responsible for driving the company,s sales growth, customer ... in healthcare, and specifically his past role in the ... the company at this pivotal time in the industry," ...
Breaking Biology Technology:Dr. J. J. Wendel Launches New Line of Skin Care Products 2Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3Global Synthetic Biology Market 2014-2018 2Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2
... 22 Fred Hutchinson Cancer Research Center,s,stem-cell transplant ... was,one of only two transplant programs nationwide that ... donor transplants, according,to an independent report that assessed ... The Center for International Blood ...
... in Genetic Engineering News for delivering the promise of safety without ... ... (PRWEB) January 22, 2009 -- InVitria,s product line was featured in ... 15, 2009 pp 32-34). The article, entitled Culture Media Underlies ...
... SAN DIEGO, Jan. 22 Axikin Pharmaceuticals, Inc., ... small molecule therapeutics for respiratory and inflammatory diseases, ... its Series A stock. The financing was ... Additional investors include Mitsui & Co. Venture ...
Cached Biology Technology:Transplant Program Tops in Expected One-Year Survival Rate 2InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication 2Axikin Pharmaceuticals Spins out of Actimis 2Axikin Pharmaceuticals Spins out of Actimis 3
(Date:7/29/2014)... San Francisco is the first to show that while ... cellular aging, these negative effects may be reduced by ... , "The study participants who exercised, slept well and ... who didn,t maintain healthy lifestyles, even when they had ... PhD, assistant professor in the department of psychiatry at ...
(Date:7/28/2014)... a circulatory problem of the legs called peripheral vascular ... surgery in serious cases. This disease can lead to ... , At The University of Texas Health Science Center ... preventative treatment in a mouse model of the disease ... Their proof-of-concept study appears in the journal Cell ...
(Date:7/28/2014)... The genome of Solanum pennellii , a wild ... an international group of researchers including the labs headed ... UC Davis Department of Plant Biology. The new genome ... , The work, published July 27 in the journal ... and colleagues at Aachen University in Germany. The UC ...
Breaking Biology News(10 mins):Healthy lifestyle may buffer against stress-related cell aging, study says 2Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2
... N.Y. Despite the fact that congenital heart ... the United States, pediatric cardiology receives relatively little attention ... volume entitled My Heart vs. the Real World ... Through striking black-and-white photographs and interviews with CHD ...
... risk by 72% in male smokers who had high ... effect on those who had low dietary vitamin C ... Journal of Nutrition. Previous studies had suggested that ... studies vitamin E seemed to protect against various infections. ...
... straight line may be the shortest distance between two ... path to follow. Thats particularly true when terrain ... have developed a mathematical model showing that a zigzag ... go up or down steep slopes. I think ...
Cached Biology News:New book gives a human face to children with congenital heart disease 2In the race to the top, zigzagging is more efficient than a straight line 2
Unit Definition: 1 U corresponds to the amount of enzyme which produces 1 mol protons per minute at pH 5.5 and 30C (peptin from citrus peel, Fluka-No. 76280, as substrate)...
Recorder, 6", 7 Day, 1 Pen, 0 to 100°C, 220V, 50/60 Hz, for 4520, Customer Installed...
... systems provide linking and labelling reagents ... specific primary antibodies for visualising cellular ... accomplished using an ultra-sensitive indirect labelling ... technology. Secondary antibodies are polymerised directly ...
Taq DNA Polymerase (T. aquaticus), 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzyme...
Biology Products: